Multiple Parties Engaged: Aurora Health Care and UPMC Adopt Cloud-based Collaboration Solution to Accelerate Clinical Research & Development; Industry Consortium PACeR Plans to Leverage Oracle Health Sciences Network to Connect Its Participants
BOSTON, June 26, 2012 /PRNewswire/ -- AG Mednet, Inc. today announced that it has signed an OEM agreement with ICON Medical Imaging, a division of ICON plc, further embedding AG Mednet's quality control, compliance, de-identification and image transfer technology into ICON's imaging trial offerings. AG Mednet provides the quality assurance and compliance technology necessary for clinical trials to operate with zero delay. The OEM partnership with AG Mednet provides ICON Medical Imaging with early insight into AG Mednet technology advancements for expanded capabilities, and will provide ICON's imaging clients with a more efficient, compliant and cost-effective clinical-trial system to expedite the clinical-trial decision-making process.
More than half of all image-related clinical trial query stoppages result from preventable human errors, according to industry research. On average, preventable mistakes delay a clinical trial for up to seven weeks, costing trial sponsors more than $8 million a day. AG Mednet's automated quality assurance technology reduces submission error rates at the source and brings preventable delays to zero.
ICON was the first imaging core laboratory to integrate with the AG Mednet solution, and this OEM agreement represents the culmination of a collaboration that recognizes AG Mednet as the industry leading solution for the collection of clinical trial medical images from study centers. "The reductions in queries, data quality issues, and time-to-receipt are fundamental components in ICON's vision of a fully automated end-to-end, zero-delay clinical trial management environment for our sites and sponsors," said Andrew Kraus, Executive Vice President of ICON Global Data Technologies.
AG Mednet's technology and services will integrate with ICON's MIRA™ and CTMS to provide sponsors and sites with the most advanced image data collection and delivery system in the market. AG Mednet supports all organizations in the clinical trial ecosystem: core labs, clinical research organizations, pharmaceutical companies and principal investigators.
"This OEM agreement is the culmination of years of collaboration and hard work between our companies," said Abraham Gutman, President and CEO of AG Mednet. "ICON Medical Imaging has a far-reaching quality management vision that will reduce the burden on sites, increase trial efficiency and strengthen protocol compliance across all therapeutic areas."
For more information about AG Mednet's product suite that dramatically increases the overall quality, accuracy and consistency of a submission while significantly decreasing clinical trial queries, please visit www.agmednet.com/zerodelay.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.